Search

Your search keyword '"Dazzi, Claudio"' showing total 157 results

Search Constraints

Start Over You searched for: Author "Dazzi, Claudio" Remove constraint Author: "Dazzi, Claudio"
157 results on '"Dazzi, Claudio"'

Search Results

2. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

3. Supplementary Table 4 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

4. Supplementary Table 1 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

5. Supplementary legend from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

6. Supplementary Table 3 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

7. Supplementary Table 2 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

8. Suppl Fig.1 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

10. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

11. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

13. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

15. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

16. Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial

17. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

23. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)

24. Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

25. Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)

26. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

27. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

30. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.

31. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

32. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

33. P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients

34. MA07.06 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial

36. P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma

37. P1.02-005 Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)

38. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.

39. Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

40. Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors.

41. Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT

44. Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

45. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

46. Association of high volume center with survival for glioblastoma patients: Results from a prospective population-based registry (PERNO).

48. Markers of sensitivity or resistance to tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring wild type EGFR.

49. The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience

Catalog

Books, media, physical & digital resources